drugset / Trial / NCT00849862

Levetiracetam 750 mg Tablets Under Fasting Conditions

NCT00849862

Phase 1 Completed 22 enrolled Teva Pharmaceuticals USA
RandomizedCrossoverOpen-label

Summary

The objective of this study is to compare the rate and extent of absorption of a test formulation of Levetiracetam and the reference Keppra® administered as a 1 x 750 mg tablet under fasting conditions.

Timeline

Start
2005-10
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 750 mg

Indications

No indication recorded.